HomeFilePharmacology

Pharmacology

View Category

Other

AHA 2019 | COLCOT: Colchicine and the Return of the Anti-Inflammatory Theory

Low-dose colchicine seems to reduce the risk for new cardiovascular events in patients with a history of...
solaci -
Learn More
Acute coronary syndromes

AHA 2019 | TWILIGHT: Discontinue Aspirin after Acute Coronary Syndrome

This study findings confirm less bleeding at no extra cost of thrombotic events when aspirin is discontinued...
solaci -
Learn More
Antithrombotic Anticoagulants

AHA 2019 | GALILEO-4D: Rivaroxaban in the Prevention of Post TAVR Valve Thickening and Thrombosis

This sub study of the GALILEO specifically looked at valve thickening and reduced leaflet motion after TAVR...
solaci -
Learn More
Other

Statins in Primary Prevention: As Questioned as Aspirin?

This new review, recently published in BMJ, questions the benefit of statins in low-risk primary prevention patients....
solaci -
Learn More
Other

What Is the Best Time to Take Antihypertensives?

Bedtime hypertensive therapy might reduce the risk of cardiovascular events according to this study soon to be...
solaci -
Learn More
Antiplatelet

Major Bleeding in Patients with Aspirin Plus Rivaroxaban

The combination of coronary artery disease or peripheral vascular disease and a reason for anticoagulation, such as...
solaci -
Learn More
Antiplatelet

Major Bleeding in Patients with Aspirin Plus Rivaroxaban

The combination of coronary artery disease or peripheral vascular disease and a reason for anticoagulation, such as...
solaci -
Learn More
Antiplatelet

THEMIS: Ischemic and Hemorrhagic Events in Delicate Balance for Chronic Ticagrelor

The THEMIS study published this week in NEJM, tested chronic ticagrelor + aspirin in diabetic patients with...
solaci -
Learn More